5 papers in the library · 14 citations · publishing 2024-2026
Contemp Clin Trials March 2, 2026 Samuel T. Wilkinson, Sandhya Prashad, Rachel Dalthorp et al. 1 citation
Non-inferiority, comparative effectiveness study of intravenous ketamine v. intranasal esketamine for treatment-resistant depression: The EQUIVALENCE trial protocol.
Clinical Therapeutics March 1, 2025 Lisa Harding, Maryia Zhdanava, Amanda Teeple et al. 3 citations
Major depressive disorder with acute suicidal ideation or behavior (MDSI) is a substantial humanistic, economic, and clinical burden on patients. Data on health care resource use (HRU) and costs among patients with MDSI initiated on esketamine nasal spray relative to traditional treatments are limited. This study sought to describe HRU and medical costs of patients with MDSI initiated on...
Frontiers in Neuroscience 2025 Christine Ramirez, Gertrude Asumpaame Alayine, Cyril Selase Kwaku Akafia et al. 3 citations
Anxiety and depression reduce autonomic system activity, as measured by Heart Rate Variability (HRV), and exacerbate cardiac morbidity. Both music and mindfulness have been shown to increase HRV, and clinical approaches incorporating these interventions show promise as effective treatments for symptoms of anxiety and depression. Music mindfulness, which combines music listening with mindfulness...
Current Medical Research and Opinion September 1, 2024 Lisa Harding, Maryia Zhdanava, Aditi Shah et al. 2 citations
In the United States (US), prescription drug coverage is subject to prior authorization (PA) criteria, which may vary between health plans and may exceed drug label requirements. This study aimed to characterize profiles and treatment history of patients with treatment-resistant depression (TRD) who initiated esketamine nasal spray, by stringency of their health plans' PA criteria relative to...
Drugs - real world outcomes June 1, 2024 Lisa Harding, Kruti Joshi, Maryia Zhdanava et al. 5 citations
This study aimed to understand treatment patterns, acute healthcare use, and cost patterns among adults with treatment-resistant depression (TRD) who completed induction treatment with esketamine nasal spray in the United States (US). Per label, induction is defined as administration twice a week for 4 weeks, after which maintenance is started on a weekly basis for 4 weeks, and thereafter,...